Lifecore Biomedical, Inc. (LFCR) Insider Trading Activity

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

Show less

Over the last 12 months, insiders at Lifecore Biomedical, Inc. have bought $7.3M and sold $9.87M worth of Lifecore Biomedical, Inc. stock.

On average, over the past 5 years, insiders at Lifecore Biomedical, Inc. have bought $6.15M and sold $9.87M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Kiper Christopher S () — $6M. WYNNEFIELD PARTNERS SMALL CAP VALUE LP I (10 percent owner) — $1.2M. Josephs Paul (Chief Executive Officer) — $97,580.

The last purchase of 17,000 shares for transaction amount of $97,580 was made by Josephs Paul (Chief Executive Officer) on 2025‑01‑08.